# Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia

> **NCT05368558** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05368558
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-18
- **Primary completion:** 2024-09-20
- **Final completion:** 2024-09-20
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368558, "Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05368558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*